Navigation Links
First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection
Date:12/12/2012

RENO, Nev., Dec. 12, 2012 /PRNewswire/ -- First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech. "We look forward to productive developments regarding the regulatory advise, marketing and distribution resources of UniCorp Biotech", says Jim Holmes, Chairman and CEO of First Waning Systems. "The Letter of Intent outlines a mutually beneficial process for defining how the capabilities of UniCorp Biotech can partner with First Warning", adds Dr. Laszlo Horvath, CEO.

"We are planning for the CE Mark process early in 2013 to be followed by clinical validation and market entry of the First Warning Systems in select European markets", says Matt Benardis, First Warning Operations Manager. "Discussions with Dr. Horvath regarding UniCorp Biotech services to expedite certification and time-to-market have been encouraging", adds Benardis.

About First Warning Systems Process
Temperature readings of breast tissue create a dynamic cell chaos profile using 9,600 points of dynamic data which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS delivers a report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents and can be used by a primary care physician.

About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS's principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russia markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com. For more information, contact: Abbi Whittaker, The Abbi Agency. (775) 323-2977, abbi@theabbiagency.com

About Unicorp Biotech
UniCorp Biotech was founded at the turn of the century. The owners desire to play a key role in the changing health care system of Europe in the area of quick and easy home access. Our company also manages (preparations, ethical permissions, monitoring) CRO projects within and outside of the European Union. We have the privilege to welcome among our customers many multinational companies acting in health care and distribution, such as Merck-Serono, Alexion, Gedeon Richter, PhamaNord, PhoenixPharma, HungaroPharma, Krka, Yamanouchi, Pliva, Tesco, Rossmann, Schlecker, Hungarian Military, National Police Headquarters. Our products are available in most pharmacies throughout Hungary and in some CEE countries. Since January of 2006, we have been the official Hungarian representatives of the Berlin-based Bayer Dermatology. UniCorp Biotech also provides information and preventive help for women, infants and Hungarians needing to be more informed, www.infertility.hu. & www.feminin.hu & www.abstinentia.hu provide assistance to those dealing with drug or other dependencies. For more information, contact: Dr. Laszlo Horvath, CEO, UniCorp Biotech Kft, H-1126 Budapest, Toth Lorincu.41., Hungary, Tel.: +36-1-393-5050, Fax: +36-1-393-5055.


'/>"/>
SOURCE First Warning Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
2. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
3. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
4. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
5. First Effective Treatment For Traumatic Brain Injury Reported by Institute of Neurological Recovery, Even Years After Injury
6. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
7. First noiseless single photon amplifier
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
9. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
11. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):